- Home
- SITE vs EWTX Comparison
SITE vs EWTX Comparison
Compare SITE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITE | EWTX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.7B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SITE | EWTX |
|---|---|---|
| Price | $100.58 | $43.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $160.38 | $39.00 |
| AVG Volume (30 Days) | 637.5K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,704,800,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.62 | N/A |
| 52 Week Low | $90.07 | $13.69 |
| 52 Week High | $168.56 | $48.40 |
Technical Indicators
Market Signals| Indicator | SITE | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 45.45 |
| Support Level | $93.10 | $37.50 |
| Resistance Level | $99.31 | $45.48 |
| Average True Range (ATR) | 2.55 | 2.08 |
| MACD | 0.61 | -0.46 |
| Stochastic Oscillator | 72.25 | 16.97 |
Price Performance
Historical ComparisonAbout SITE SiteOne Landscape Supply Inc.
SiteOne Landscape Supply Inc is a national full product line wholesale distributor of landscape supplies in the United States and has an established presence in Canada. Its customers are mainly residential and commercial landscape professionals who specialized in the design, installation, and maintenance of lawns, gardens, golf courses, and other outdoor spaces.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.